Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 593

1.

Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.

Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH.

Maturitas. 2009 Aug 20;63(4):329-35. doi: 10.1016/j.maturitas.2009.06.006. Epub 2009 Jul 31.

PMID:
19647382
2.

Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.

Bachmann G, Bobula J, Mirkin S.

Climacteric. 2010 Apr;13(2):132-40. doi: 10.3109/13697130903305627.

PMID:
19863455
3.

Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.

Pinkerton JV, Pan K, Abraham L, Racketa J, Ryan KA, Chines AA, Mirkin S.

Menopause. 2014 Mar;21(3):252-9. doi: 10.1097/GME.0b013e31829f0433.

PMID:
23942245
4.

Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.

Yu H, Racketa J, Chines AA, Mirkin S.

Climacteric. 2013 Apr;16(2):252-7. doi: 10.3109/13697137.2012.717996. Epub 2012 Oct 4.

PMID:
23035721
5.

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G.

Fertil Steril. 2009 Sep;92(3):1025-38. doi: 10.1016/j.fertnstert.2009.03.113. Epub 2009 Jul 26.

PMID:
19635615
6.

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.

Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH.

Menopause. 2009 Nov-Dec;16(6):1116-24. doi: 10.1097/gme.0b013e3181a7df0d. Erratum in: Menopause. 2015 Feb;22(2):245.

PMID:
19546826
7.

Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.

Pinkerton JV, Pickar JH, Racketa J, Mirkin S.

Climacteric. 2012 Oct;15(5):411-8. doi: 10.3109/13697137.2012.696289. Epub 2012 Aug 1. Review.

PMID:
22853444
8.

Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.

Bushmakin AG, Abraham L, Pinkerton JV, Cappelleri JC, Mirkin S.

Menopause. 2014 Aug;21(8):815-22. doi: 10.1097/GME.0000000000000176.

PMID:
24378765
9.

Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.

Pinkerton JV, Bushmakin AG, Racketa J, Cappelleri JC, Chines AA, Mirkin S.

Menopause. 2014 Mar;21(3):243-51. doi: 10.1097/GME.0b013e31829f05d1.

PMID:
23899830
10.

Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S.

J Womens Health (Larchmt). 2014 Jan;23(1):18-28. doi: 10.1089/jwh.2013.4392. Epub 2013 Nov 9.

PMID:
24206058
11.

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.

Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH.

Fertil Steril. 2009 Sep;92(3):1039-44. doi: 10.1016/j.fertnstert.2009.05.093. Epub 2009 Jul 26.

PMID:
19635614
12.

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.

Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.

Menopause. 2010 Mar;17(2):281-9. doi: 10.1097/GME.0b013e3181b7c65f.

PMID:
19779382
13.

Tissue-selective estrogen complexes for postmenopausal women.

Mirkin S, Komm BS.

Maturitas. 2013 Nov;76(3):213-20. doi: 10.1016/j.maturitas.2013.06.003. Epub 2013 Jul 11. Review.

PMID:
23849704
14.

Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.

Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S.

Maturitas. 2014 Jul;78(3):212-8. doi: 10.1016/j.maturitas.2014.04.008. Epub 2014 Apr 26. Erratum in: Maturitas. 2014 Dec;79(4):488.

PMID:
24837362
15.

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

Taylor HS, Ohleth K.

Menopause. 2012 Apr;19(4):479-85. doi: 10.1097/gme.0b013e31823dbbca. Review.

PMID:
22278343
16.

Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.

Gallagher JC, Shi H, Mirkin S, Chines AA.

Menopause. 2013 Nov;20(11):1126-32. doi: 10.1097/GME.0b013e31828ac8cc.

PMID:
23632659
17.

Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.

Pickar JH, Mirkin S.

Menopause Int. 2010 Sep;16(3):121-8. doi: 10.1258/mi.2010.010033. Review.

PMID:
20956688
18.

Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.

Pinkerton JV, Stovall DW.

Expert Opin Investig Drugs. 2010 Dec;19(12):1613-21. doi: 10.1517/13543784.2010.532487. Epub 2010 Nov 13. Review.

PMID:
21073353
19.

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

Pickar JH, Yeh IT, Bachmann G, Speroff L.

Fertil Steril. 2009 Sep;92(3):1018-24. doi: 10.1016/j.fertnstert.2009.05.094. Epub 2009 Jul 26.

PMID:
19635613
20.

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.

Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV.

J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. Epub 2016 Sep 27.

PMID:
27676118

Supplemental Content

Support Center